Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Poniard Pharmaceuticals Inc.

Latest From Poniard Pharmaceuticals Inc.

BioNotebook: Up to $2.6bn in post-JP Morgan stock offerings, plus six IPO updates

Public biotechnology companies took advantage of excitement for the industry that was generated during the JP Morgan Healthcare Conference from 12 to 15 January in San Francisco by announcing plans to raise up to $2.6bn from stock offerings that will fund acquisitions, clinical trials and regulatory filings.

Cancer Orthopedics

Life Science Start-Ups: Tech Transfer Deals, April 2014

Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2014.

BioPharmaceutical Medical Device

BioNotebook: Merck drops Ariad's ridaforolimus; United Therapeutics, Infinity, Verastem updates; Dipexium, Achaogen IPO terms

Ariad will regain ridaforolimus rights from Merck in November; United Therapeutics considers deals, protects patents; Infinity secures new debt; Verastem buys back VS-4718 rights; and Dipexium, Achaogen set IPO terms.

Cardiovascular Cancer

Verastem Trumpets Early Clinical Results For FAK Program, Discloses Timelines And Plans

Addressing an audience of 150 attendees at its first clinical-stage R&D day on July 11, Verastem Inc. put forward its new senior executive team, as well as an eminent authority in cancer stem cell biology, to describe its clinical progress thus far, and its future plans.

BioPharmaceutical Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • NeoRx Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Poniard Pharmaceuticals Inc.
  • Senior Management
  • Michael K Jackson, Interim CFO
    Cheni Kwok, PhD, SVP, Corp. Dev.
    Michael S Perry, PhD, Pres & CMO
  • Contact Info
  • Poniard Pharmaceuticals Inc.
    Phone: (650) 583-3774
    750 Battery St., Ste. 330
    San Francisco, CA 94111